Jinlu Shan

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study

Feng Bi, Shukui Qin, Yuxian Bai, Zhendong Chen et autres

BACKGROUND AND AIMS: Donafenib, a deuterium-modified sorafenib derivative, has improved survival outcomes in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the treatment-related adverse events and their associations with overall survival (OS) and time to progression (TTP) in patients …

cn, au (code pays fourni par la source)

Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer

Lingbo Bao, Xudong Wang, Xiuyong Liao, Li Dong et autres

BACKGROUND: Despite frequent Epidermal Growth Factor Receptor (EGFR) amplification and overexpression in gastric cancer, limited therapeutic responses were observed in existing EGFR-targeted agents. Pyrotinib, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor, has shown clinical efficacy in HER2-driven malignancies, but its potential role …

cn (code pays fourni par la source)

Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.

Yakun Wang, Jifang Gong, Mingjun Zhang, Yuping Sun et autres

2527 Background: QLS31905 is a Claudin18.2/CD3 bispecific antibody. Here we report the updated data of a phase 1 study of QLS31905. Methods: This multicenter phase 1 trial (NCT05278832) recruited patients (pts) with advanced solid tumors who had progressive disease or were intolerable …

cn (code pays fourni par la source)

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu et autres

cn (code pays fourni par la source)

Additional file 2 of Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer

Lingbo Bao, Xudong Wang, Xiuyong Liao, Dong Li et autres

Supplementary Material 2

cn, pk (code pays fourni par la source)

Additional file 1 of Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer

Lingbo Bao, Xudong Wang, Xiuyong Liao, Dong Li et autres

Supplementary Material 1

cn, pk (code pays fourni par la source)

Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study

Qing Hua Zhou, Nong Yang, Mingfang Zhao, Dingzhi Huang et autres

cn (code pays fourni par la source)

Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study

Qing Wei Zhou, Xiangjiao Meng, Longhua Sun, Dingzhi Huang et autres

cn (code pays fourni par la source)

Targeted Regulation of Osteoblasts and Osteoclasts in Osteosarcoma Patients by CSF3R Receptor Inhibition of Osteolysis Caused by Tumor Inflammation Based on Transcriptional Spectrum Analysis and Drug Library Screening

Wei Duan, Yu Chen, Jinlu Shan, Qian Li

BACKGROUND: Osteosarcoma (OS) is a common primary malignant bone tumor that mainly occurs in children and adolescents. The use of IL-8 inhibitor compounds has been reported in patents, which can be used to treat and/or prevent osteosarcoma, but the pathogenesis of osteosarcoma …

cn (code pays fourni par la source)

Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE)

Yuankai Shi, Jianhua Chen, Runxiang Yang, Hongbo Wu et autres

INTRODUCTION: Iruplinalkib (WX-0593) is a new-generation, potent ALK tyrosine kinase inhibitor (TKI) that has been found to have systemic and central nervous system (CNS) efficacy in ALK-positive NSCLC. We compared the efficacy and safety of iruplinalkib with crizotinib in patients with ALK …

cn, us (code pays fourni par la source)

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Shun Lü, Wei Dong Zhang, Lin Wu, Wenxiang Wang et autres

Importance: Adjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non-small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown. Objective: To determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free …

cn, us (code pays fourni par la source)

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang et autres

Immune checkpoint inhibitor (ICI) rechallenge in non-small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while …

cn, us, Éthiopie (code pays fourni par la source)